Despite a higher FGFR1 level in brain metastases originating from NSCLC adenocarcinomas (15.3%)30, FGFR1 amplification is somewhat lower in adenocarcinomas compared to squamous NSCLC (2.2-4.1%)31,32. The gene discussed is FGFR1; the disease is adenocarcinoma.